野村发表报告，预计药明合联(02268.HK) 2025年下半年业绩或逊预期。公司发盈喜，预计2025财年收入、毛利、经调整净利润及股东应占净利润按年增长分别超过45%、70%、45%及38%。该行予其“买入”评级，目标价82.72元。该行推算公司2025年下半年销售收入按年增长33%至31.8亿元人民币(下同)，低于市场预期33.3亿元及该行原先预估34.8亿元，毛利达11.3亿元、意味毛利率...
Source Link野村发表报告，预计药明合联(02268.HK) 2025年下半年业绩或逊预期。公司发盈喜，预计2025财年收入、毛利、经调整净利润及股东应占净利润按年增长分别超过45%、70%、45%及38%。该行予其“买入”评级，目标价82.72元。该行推算公司2025年下半年销售收入按年增长33%至31.8亿元人民币(下同)，低于市场预期33.3亿元及该行原先预估34.8亿元，毛利达11.3亿元、意味毛利率...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.